Selective targeting of BD1 and BD2 of the BET proteins in cancer and immuno-inflammation

Journal: Science

Published: 2020-04-24

DOI: 10.1126/science.aaz8455

Affiliations: 7

Authors: 37

Go to article
Institutions Share
GlaxoSmithKline Stevenage, United Kingdom (UK) 0.51
Cellzome GmbH, Germany 0.19
Peter MacCallum Cancer Centre (Peter Mac), Australia 0.13
Sir Peter MacCallum Department of Oncology, UniMelb, Australia 0.07
Promega Corporation, United States of America (USA) 0.05
GlaxoSmithKline USA, United States of America (USA) 0.03
University of Melbourne Centre for Cancer Research (UMCCR), UniMelb, Australia 0.02

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER